Literature DB >> 12019357

Melatonin and the cardiovascular system.

Ewa Sewerynek1.   

Abstract

Melatonin concentrations in serum, as well as urinary levels of its main metabolite, 6-sulphatoxymelatonin, decrease with age. In the course of aging, the frequency of heart diseases, both acute and chronic, systematically increases. The evidence from the last 10 years suggests that melatonin influences the cardiovascular system. The presence of vascular melatoninergic receptors/binding sites has been demonstrated; these receptors are functionally linked with vasoconstrictor or vasodilatory effects of melatonin. Melatonin can contribute in cardioprotection of the rat heart, following myocardial ischemia. It has been shown that patients with coronary heart disease have a low melatonin production rate, especially those with higher risk of cardiac infarction and/or sudden death. There are clinical data reporting some alterations of melatonin in human stroke and coronary heart disease. The suprachiasmatic nucleus and, possibly, the melatoninergic system may also modulate cardiovascular rhythmicity. Hypercholesterolemia and hypertension are the other age-related symptoms. People with high levels of LDL-cholesterol have low levels of melatonin. It has been shown that melatonin suppresses the formation of cholesterol by 38% and reduces LDL accumulation by 42%. A 10-20% reduction of cholesterol concentration in women using the B-oval pill has been observed. It is a very important because, even a 10-15% reduction in blood cholesterol concentration has bee shown to result in a 20 to 30% decrease in the risk of coronary heart disease. People with hypertension have lower melatonin levels than those with normal blood pressure. The administration of the hormone in question declines blood pressure to normal range. It has been observed that melatonin, even in a dose 1 mg, reduced blood pressure and decreased catecholamine level after 90 min in human subjects. Melatonin may reduce blood pressure via the following mechanisms: 1) by a direct effect on the hypothalamus; 2) as an antioxidant which lowers blood pressure; 3) by decreasing the level of catecholamines, or 4) by relaxing the smooth muscle in the aorta wall.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019357

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  28 in total

Review 1.  The therapeutic potential of melatonin: a review of the science.

Authors:  Samir Malhotra; Girish Sawhney; Promila Pandhi
Journal:  MedGenMed       Date:  2004-04-13

2.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

3.  Cardiovascular Responses to Tonic Pain in REM Sleep-Deprived Rats: Role of Melatonin and Beta Endorphin.

Authors:  Salah Kassab; Usha Sachdeva; Nagalla Das; Tarik Al-Shaibani; Usha Nayar
Journal:  Sultan Qaboos Univ Med J       Date:  2006-06

4.  Myocardial ischemia-reperfusion injury: Possible role of melatonin.

Authors:  Alberto Dominguez-Rodriguez; Pedro Abreu-Gonzalez
Journal:  World J Cardiol       Date:  2010-08-26

Review 5.  Complementary and alternative medicine for sleep disturbances in older adults.

Authors:  Nalaka S Gooneratne
Journal:  Clin Geriatr Med       Date:  2008-02       Impact factor: 3.076

6.  Dose-dependent dual effect of melatonin on ototoxicity induced by amikacin in adult rats.

Authors:  Tamer Erdem; Orhan Ozturan; Mustafa Iraz; Murat Cem Miman; Ercument Olmez
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-05-28       Impact factor: 2.503

Review 7.  The antiapoptotic activity of melatonin in neurodegenerative diseases.

Authors:  Xin Wang
Journal:  CNS Neurosci Ther       Date:  2009-10-10       Impact factor: 5.243

8.  The association between phenomena on the sun, geomagnetic activity, meteorological variables, and cardiovascular characteristic of patients with myocardial infarction.

Authors:  Jone Vencloviene; Ruta Babarskiene; Rimvydas Slapikas; Gintare Sakalyte
Journal:  Int J Biometeorol       Date:  2012-11-24       Impact factor: 3.787

Review 9.  Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology.

Authors:  Stefano Comai; Gabriella Gobbi
Journal:  J Psychiatry Neurosci       Date:  2014-01       Impact factor: 6.186

10.  Urinary 6-sulfatoxymelatonin level in age-related macular degeneration patients.

Authors:  Richard Rosen; Dan-Ning Hu; Violete Perez; Katy Tai; Guo-Pei Yu; Min Chen; Paul Tone; Steven A McCormick; Joseph Walsh
Journal:  Mol Vis       Date:  2009-08-21       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.